UPS
MCID: UND005
MIFTS: 44

Undifferentiated Pleomorphic Sarcoma (UPS) malady

Categories: Rare diseases, Bone diseases, Cancer diseases

Aliases & Classifications for Undifferentiated Pleomorphic Sarcoma

Aliases & Descriptions for Undifferentiated Pleomorphic Sarcoma:

Name: Undifferentiated Pleomorphic Sarcoma 50 56
Malignant Fibrous Histiocytoma 50 13 52 69
Ups 50 56
Malignant Fibrohistiocytic Tumors 50

Characteristics:

Orphanet epidemiological data:

56
undifferentiated pleomorphic sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (United States); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: any age;

Classifications:

Orphanet: 56  
Rare bone diseases


External Ids:

Orphanet 56 ORPHA2023
MESH via Orphanet 43 D051677
UMLS via Orphanet 70 C0334463
ICD10 via Orphanet 34 C49.9

Summaries for Undifferentiated Pleomorphic Sarcoma

MalaCards based summary : Undifferentiated Pleomorphic Sarcoma, also known as malignant fibrous histiocytoma, is related to melanocytic nevus syndrome, congenital, somatic and amyloidosis, hereditary, transthyretin-related. An important gene associated with Undifferentiated Pleomorphic Sarcoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Cytoskeletal Signaling. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, heart and ovary, and related phenotypes are Decreased cell migration and cardiovascular system

Wikipedia : 71 Pleomorphic undifferentiated sarcoma (abbreviated PUS), also undifferentiated pleomorphic sarcoma and... more...

Related Diseases for Undifferentiated Pleomorphic Sarcoma

Diseases related to Undifferentiated Pleomorphic Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 614)
id Related Disease Score Top Affiliating Genes
1 melanocytic nevus syndrome, congenital, somatic 30.9 KRAS PIK3CA
2 amyloidosis, hereditary, transthyretin-related 30.3 DES MET VIM
3 desmoid tumor 29.6 ACTC1 VIM
4 gastrointestinal stromal tumor 29.5 ACTC1 DES VIM
5 diaphyseal medullary stenosis with malignant fibrous histiocytoma 12.7
6 malignant fibrous histiocytoma of bone 12.3
7 ichthyosis tapered fingers midline groove up 11.8
8 kabuki syndrome 1 11.6
9 urticaria pigmentosa 11.1
10 porphyria, acute intermittent 10.9
11 wilson disease 10.9
12 cystic fibrosis 10.8
13 lung cancer 10.8
14 duchenne muscular dystrophy 10.8
15 esophageal cancer 10.8
16 narcolepsy 10.8
17 pulmonary embolism 10.8
18 neuronal ceroid lipofuscinosis 10.8
19 refractive error 10.8
20 rippling muscle disease 10.8
21 pigment dispersion syndrome 10.8
22 frontotemporal lobar degeneration with ubiquitin-positive inclusions 10.8
23 breast cancer 10.8
24 ulcerative colitis 10.8
25 amyloidosis 10.8
26 atherosclerosis 10.7
27 phenylketonuria 10.7
28 west syndrome 10.7
29 bipolar disorder 10.7
30 intrahepatic cholestasis 10.7
31 hemochromatosis 10.7
32 cystinosis 10.7
33 hiatus hernia 10.7
34 poliomyelitis 10.7
35 al amyloidosis 10.7
36 metachromatic leukodystrophy 10.7
37 niemann-pick disease 10.7
38 spinal cord injury 10.7
39 neurofibromatosis 10.7
40 peripheral vascular disease 10.7
41 cluster headache 10.7
42 gout 10.7
43 peripheral artery disease 10.7
44 chronic thromboembolic pulmonary hypertension 10.7
45 transient cerebral ischemia 10.7
46 hypoxia 10.7
47 bronchitis 10.7
48 postural orthostatic tachycardia syndrome 10.7
49 lymphedema 10.7
50 lesch-nyhan syndrome 10.7

Graphical network of the top 20 diseases related to Undifferentiated Pleomorphic Sarcoma:



Diseases related to Undifferentiated Pleomorphic Sarcoma

Symptoms & Phenotypes for Undifferentiated Pleomorphic Sarcoma

GenomeRNAi Phenotypes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 8.92 KRAS MET PIK3CA VIM

MGI Mouse Phenotypes related to Undifferentiated Pleomorphic Sarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.63 ACTC1 DES KRAS MET PIK3CA VIM
2 cellular MP:0005384 9.43 ACTC1 DES KRAS MET PIK3CA VIM
3 muscle MP:0005369 9.1 ACTC1 DES KRAS MET PIK3CA VIM

Drugs & Therapeutics for Undifferentiated Pleomorphic Sarcoma

Drugs for Undifferentiated Pleomorphic Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
9
Lenograstim Approved Phase 3 135968-09-1
10
Dactinomycin Approved Phase 3 50-76-0 2019 457193
11
Epirubicin Approved Phase 3 56420-45-2 41867
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
15
Cyproheptadine Approved Phase 3 129-03-3 2913
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
17
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Anti-Infective Agents Phase 3,Phase 2,Phase 1
22 Isophosphamide mustard Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
25 Antiviral Agents Phase 3,Phase 2,Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
27 Etoposide phosphate Phase 3,Phase 2
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
29 Antimitotic Agents Phase 3,Phase 2,Phase 1
30 Antirheumatic Agents Phase 3,Phase 2,Phase 1
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
34 Dermatologic Agents Phase 3,Phase 2
35
Histamine Phosphate Phase 3 51-74-1 65513
36
Serotonin Phase 3 50-67-9 5202
37 Serotonin Agents Phase 3
38 Serotonin Antagonists Phase 3
39 Gastrointestinal Agents Phase 3
40 Neurotransmitter Agents Phase 3
41 Histamine Antagonists Phase 3
42 Histamine H1 Antagonists Phase 3
43 Anti-Allergic Agents Phase 3
44 Antipruritics Phase 3
45
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
46
Indinavir Approved Phase 2 150378-17-9 5362440
47
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
48
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
49
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
50
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 58)
id Name Status NCT ID Phase
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
4 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
5 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
7 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
8 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
12 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
13 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3
14 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
15 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3
16 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
17 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
18 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
19 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
20 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2
21 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2
22 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
23 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
24 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
25 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2
26 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
27 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
28 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2
29 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2
30 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2
31 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
32 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
33 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2
34 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2
35 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
36 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
37 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting NCT02815995 Phase 2
38 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2
39 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2
40 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2
41 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Recruiting NCT02301039 Phase 2
42 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2
43 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Active, not recruiting NCT01653028 Phase 2
44 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Not yet recruiting NCT03123276 Phase 1, Phase 2
45 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Not yet recruiting NCT02923778 Phase 2
46 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2
47 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
48 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1
49 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1
50 Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00030784 Phase 1

Search NIH Clinical Center for Undifferentiated Pleomorphic Sarcoma

Genetic Tests for Undifferentiated Pleomorphic Sarcoma

Anatomical Context for Undifferentiated Pleomorphic Sarcoma

MalaCards organs/tissues related to Undifferentiated Pleomorphic Sarcoma:

39
Bone, Heart, Ovary, Testes, Skin, Lung, Colon

Publications for Undifferentiated Pleomorphic Sarcoma

Articles related to Undifferentiated Pleomorphic Sarcoma:

(show top 50) (show all 53)
id Title Authors Year
1
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. ( 27900663 )
2017
2
LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome. ( 28079637 )
2017
3
Tail of Superficial Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma After Preoperative Radiotherapy. ( 27127141 )
2016
4
Radiation-induced undifferentiated pleomorphic sarcoma after radiation therapy for a desmoid tumour. ( 26725422 )
2016
5
High prevalence of MiTF staining in undifferentiated pleomorphic sarcoma: caution in use of melanocytic markers in sarcoma. ( 27926791 )
2016
6
Undifferentiated pleomorphic sarcoma of the vocal fold. ( 27929601 )
2016
7
High-grade undifferentiated pleomorphic sarcoma of the pelvis: A case report and review of literature. ( 27453666 )
2016
8
An unusual cause of life-threatening right-sided heart failure: undifferentiated pleomorphic sarcoma in the right ventricular outflow tract. ( 26670651 )
2016
9
Study of Epithelial to Mesenchymal Transition in Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma to Discern an Epithelial Origin. ( 26999338 )
2016
10
Undifferentiated Pleomorphic Sarcoma Presenting as Abdominal Pain with a Pulsatile Mass. ( 27563479 )
2016
11
Successful Salvage Radiotherapy for a Chemo-refractory, Non-resectable, Undifferentiated Pleomorphic Sarcoma Lung Metastasis with Pericardial Involvement: A Case Report. ( 26918213 )
2016
12
Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. ( 26847678 )
2016
13
Undifferentiated pleomorphic sarcoma with focally rhabdomyosarcomatous differentiation of the ovary. ( 27352574 )
2016
14
Intraventricular Undifferentiated Pleomorphic Sarcoma: A Case Report. ( 28003940 )
2016
15
Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. ( 27446424 )
2016
16
RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas. ( 26479291 )
2016
17
Primary undifferentiated pleomorphic sarcoma of the breast in a young female: a case report. ( 27421259 )
2016
18
Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma. ( 26759307 )
2016
19
Phosphorylation of STAT3 in Undifferentiated Pleomorphic Sarcoma Is Correlated with a Favorable Prognosis. ( 27652596 )
2016
20
Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma. ( 25516889 )
2015
21
Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions. ( 25743327 )
2015
22
Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma. ( 26502919 )
2015
23
Emerging targets in sarcoma: Rising to the challenge of RAS signaling in undifferentiated pleomorphic sarcoma. ( 26479175 )
2015
24
Cutaneous Metastatic Undifferentiated Pleomorphic Sarcoma from a Mediastinal Sarcoma. ( 26082589 )
2015
25
Primary Mesenteric Undifferentiated Pleomorphic Sarcoma Masquerading as a Colon Carcinoma: A Case Report and Review of the Literature. ( 26380135 )
2015
26
MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas. ( 25844809 )
2015
27
Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology. ( 26553363 )
2015
28
MFH and high-grade undifferentiated pleomorphic sarcoma-what's in a name? ( 25219789 )
2015
29
Undifferentiated pleomorphic sarcoma with co-existence of KRAS/PIK3CA mutations. ( 26339434 )
2015
30
Life-threatening acute heart failure due to primary cardiac undifferentiated pleomorphic sarcoma. ( 25130109 )
2014
31
Gene expression profiling in leiomyosarcomas and undifferentiated pleomorphic sarcomas: SRC as a new diagnostic marker. ( 25028927 )
2014
32
Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: A miRNA analysis. ( 24771630 )
2014
33
Numerical and structural chromosomal anomalies in undifferentiated pleomorphic sarcoma. ( 25503139 )
2014
34
Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas? ( 24525499 )
2014
35
A novel use of foley catheters to prevent injury to the pelvic viscera during stereotactic radiosurgery for undifferentiated pleomorphic sarcoma of the sacrum. ( 25102522 )
2014
36
High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event. ( 24804818 )
2014
37
Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. ( 24975462 )
2014
38
Left atrial high-grade undifferentiated pleomorphic sarcoma protruding through the mitral valve. ( 25468101 )
2014
39
An unusual case of metastasis of a pulmonary undifferentiated pleomorphic sarcoma to the right ventricle: a case report. ( 23805953 )
2013
40
Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma. ( 23000905 )
2013
41
Gastrointestinal stromal tumor with dedifferentiation to undifferentiated pleomorphic sarcoma. ( 24200161 )
2013
42
Genomic signatures predict poor outcome in undifferentiated pleomorphic sarcomas and leiomyosarcomas. ( 23825676 )
2013
43
Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature. ( 23672746 )
2013
44
Pleomorphic malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma of the glans penis. ( 24475005 )
2013
45
[A case of undifferentiated pleomorphic sarcoma of the stomach showing rapid growth]. ( 23831658 )
2013
46
Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. ( 21316601 )
2011
47
Thymoma with coexisting undifferentiated pleomorphic sarcoma: a case report. ( 22937421 )
2011
48
Undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma) of the head in a dog. ( 20877156 )
2011
49
Aberrant Melan-A expression in atypical fibroxanthoma and undifferentiated pleomorphic sarcoma of the skin. ( 22050092 )
2011
50
Undifferentiated pleomorphic sarcoma (so-called malignant fibrous histiocytoma) of the inferior vena cava with extension into the right atrium. ( 20350229 )
2010

Variations for Undifferentiated Pleomorphic Sarcoma

Expression for Undifferentiated Pleomorphic Sarcoma

Search GEO for disease gene expression data for Undifferentiated Pleomorphic Sarcoma.

Pathways for Undifferentiated Pleomorphic Sarcoma

Pathways related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1 12.3 KRAS MET PIK3CA
2 12.23 ACTC1 DES VIM
3
Show member pathways
12.19 KRAS MET PIK3CA
4
Show member pathways
12.11 KRAS MET PIK3CA
5
Show member pathways
12.08 KRAS PIK3CA VIM
6
Show member pathways
11.93 KRAS MET PIK3CA
7 11.81 KRAS MET PIK3CA
8 11.73 KRAS MET PIK3CA VIM
9 11.68 KRAS MET PIK3CA
10 11.26 MET PIK3CA
11
Show member pathways
11.23 DES VIM
12 11.19 ACTC1 DES VIM
13
Show member pathways
11.18 MET PIK3CA
14 11.14 ACTC1 MET
15 11.09 KRAS PIK3CA
16 10.97 MET PIK3CA
17 10.93 KRAS MET
18 10.91 KRAS PIK3CA
19 10.8 KRAS PIK3CA
20 10.61 KRAS MET PIK3CA

GO Terms for Undifferentiated Pleomorphic Sarcoma

Biological processes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.5 ACTC1 KRAS VIM
2 epidermal growth factor receptor signaling pathway GO:0007173 9.37 KRAS PIK3CA
3 cardiac muscle contraction GO:0060048 9.26 ACTC1 PIK3CA
4 ERBB2 signaling pathway GO:0038128 9.16 KRAS PIK3CA
5 intermediate filament organization GO:0045109 8.96 DES VIM
6 muscle filament sliding GO:0030049 8.8 ACTC1 DES VIM

Sources for Undifferentiated Pleomorphic Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....